Aquestive Therapeutics, Inc.
Warren, New Jersey, United States · Biopharma, Biotechnology, Healthcare
Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. The company specializes in drug delivery technologies and is committed to improving patients' lives through its product pipeline. Their product candidate, Anaphylm™, aims to provide a new treatment option for severe allergic reactions. The company is headqua
Key facts
- Headquarters
- Warren, New Jersey, United States
- Employees
- 150
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (AQST)
- Website
- aquestive.com
Recent activity at Aquestive Therapeutics, Inc.
- : Aquestive Therapeutics Enters License Agreement with Eton Pharmaceuticals for LIBERVANT® (date Fundz recorded it)
- : Richard J. Daly Appointed as Director of Aquestive Therapeutics
- : SEC 8-K (7.01): Aquestive Therapeutics, Inc. is disclosing information through an investor presentation provided at the Jefferies Global Healthcare Conference on November 16, 2026. This presentation aims to share insights with institutional investors, analysts, and other stakeholders about the Company's business operations and future outlook. The information is subject to updates and can be accessed via the Company’s website, although the Company may choose to discontinue this access at any time. The presentation is attached as Exhibit 99.1 and will not be considered 'filed' under specific sections of the Securities Exchange Act.
- : SEC 8-K (7.01): Aquestive Therapeutics, Inc. is disclosing information related to an investor presentation scheduled for distribution at meetings with institutional investors and analysts. This event aims to provide insights into the Company’s strategic direction and project updates. The presentation is available online and may be updated through future filings. Notably, the presentation was dated November 2026, indicating its relevance to current discussions with potential investors. This proactive communication is intended to enhance investor relations and transparency.
- : SEC 8-K (7.01): This filing includes a Regulation FD Disclosure regarding an investor presentation to be conducted by Aquestive Therapeutics, Inc. on November 3, 2026. The presentation will be shared with institutional investors and analysts, providing insights into the company’s financial performance and recent developments. Accompanying this disclosure are the Q3 earnings supplemental materials and a press release detailing the financial results for the third quarter ended September 30, 2026. This information aims to maintain transparency and keep stakeholders informed about the company's strategic direction.
- : SEC 8-K (7.01): On October 15, 2026, Aquestive Therapeutics, Inc. announced the FDA's acknowledgment of its resubmission of the New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film, intended for treating Type I allergic reactions, including anaphylaxis. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of March 16, 2027, indicating the timeline for the agency's decision on the NDA. This disclosure is critical as it highlights significant progress in the drug approval process, which could impact the company's market position and future revenues.
- : SEC 8-K (1.01): On October 13, 2026, Aquestive Therapeutics, Inc. entered into a license agreement with Eton Pharmaceuticals, Inc. granting Eton exclusive U.S. rights to commercialize LIBERVANT® (diazepam) buccal film, which is for the acute treatment of seizure clusters in patients with epilepsy. Aquestive received an upfront license fee of $10 million and may receive up to $47.5 million in additional milestone payments based on performance, including specific sales milestones and regulatory approvals. The agreement includes a 20-year supply agreement where Aquestive will be the exclusive manufacturer of the product, subject to renewal conditions. This collaboration aims to enhance the availability of the product for treating seizure clusters in targeted age groups, which may significantly influence both companies' market positions.
- : SEC 8-K (5.02): On September 29, 2026, Aquestive Therapeutics, Inc. announced that Richard J. Daly has been elected as a director of the Company, effective October 14, 2026. Mr. Daly will serve as a Class I director with a term that will expire at the Company's 2028 Annual Meeting of Stockholders. The announcement regarding Mr. Daly's election was made through a press release on the same date, highlighting a strategic move by the Board of Directors to strengthen its governance. This change reflects the Company's ongoing efforts to enhance leadership and oversight.
- : SEC 8-K (7.01): Aquestive Therapeutics, Inc. is providing a Regulation FD Disclosure in connection with an investor presentation to be held on September 23, 2026. This presentation includes information intended for institutional investors and analysts, and aims to update stakeholders on the company's developments and strategies. A copy of the investor presentation is available on the company's website, reflecting its commitment to transparency in communications with investors.
- : SEC 8-K (7.01): Aquestive Therapeutics, Inc. provided a Regulation FD disclosure regarding an investor presentation during the H.C. Wainwright 28th Annual Global Investor Conference held on September 14, 2026. This presentation was aimed at institutional investors, analysts, and others to share significant updates about the company. The event included insights into the company's operations and future strategies. The presentation could potentially influence investor perception and decision-making regarding the company's stock. A copy of the presentation is attached as Exhibit 99.2 in this filing.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Aquestive Therapeutics, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| May 2018 | Venture | $9.1M |
Leadership
- Milosz Blyszczek, Senior Director Clinical Operations
- Santo Costa, Director
- James Scibetta, Director
- John Cochran, Director
- Gregory Brown, Director
- Douglas Bratton, Director
- A. Shobel, Executive Officer, Director
- Keith Kendall, Executive Officer, Director
- Richard J. Daly, Director
- Lori J. Braender, Chief Compliance Officer
- Matthew Greenhawt, Chief Medical Officer
- Theresa Wood, Executive Officer
Verified email and direct lines for Aquestive Therapeutics, Inc.’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Aquestive Therapeutics, Inc. files 1 employee benefit plan with the U.S. Department of Labor. The next plan year renews in Dec 2026.
Aquestive Therapeutics, Inc. in the news
- Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewswire (Nov 09, 2026)
- Aquestive Therapeutics Announces Regulatory Development for Anaphylm Sublingual Film and Provides Business Update - Investing News Network (Jan 09, 2026)
- Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET - The Manila Times (Oct 27, 2026)
- Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly - GlobeNewswire (Sep 29, 2026)
- Aquestive Therapeutics Announces FDA Acceptance of - GlobeNewswire (Oct 15, 2026)
- Aquestive Therapeutics Announces Resubmission of New Drug - GlobeNewswire (Sep 17, 2026)
- Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree - GlobeNewswire (May 12, 2026)
Companies similar to Aquestive Therapeutics, Inc.
- Lipella Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Medical, Pharmaceutical, Therapeutics
- Savara Inc · Biopharma, Biotechnology, Healthcare, Health Care, Medical, Pharmaceutical, Therapeutics
- Parabilis Medicines · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- InnoCare Pharma · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Citius Oncology · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
About Aquestive Therapeutics, Inc.: questions and answers
What does Aquestive Therapeutics, Inc. do?
Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. The company specializes in drug delivery technologies and is committed to improving patients' lives through its product pipeline. Their product candidate, Anaphylm™, aims to provide a new treatment option for severe allergic reactions. The company is headqua
Where is Aquestive Therapeutics, Inc. headquartered?
Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey, United States.
How many employees does Aquestive Therapeutics, Inc. have?
Aquestive Therapeutics, Inc. has about 150 employees.
Has Aquestive Therapeutics, Inc. raised funding?
Yes. Fundz has recorded 1 funding event for Aquestive Therapeutics, Inc.. The most recent, $9.1M, was in May 2018.
What is the latest news on Aquestive Therapeutics, Inc.?
On Oct 14, 2026, Aquestive Therapeutics Enters License Agreement with Eton Pharmaceuticals for LIBERVANT®
Is Aquestive Therapeutics, Inc. a public company?
Yes. Aquestive Therapeutics, Inc. is publicly traded under the ticker AQST.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy